Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
September 13, 2024
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
Meet the women who want to bring us back to the Dark Ages -- or to a future envisioned by Margaret Atwood.
Gilead Sciences Inc. prepared to expand its reach further beyond AIDS drugs Monday after federal regulators approved the biotech drug maker's signature anti-HIV therapy as a hepatitis B treatment.
The activist group wants the federal government to reject a patent extension for Gilead's tenofovir alafenamide, a component of several HIV meds.
The pharmaceutical company formed a transgender board of advisers, which guided how to distribute the historic donation.
The congresswoman asked why the HIV prevention drug costs nearly $2,000 in the U.S. but only $8 in Australia.
The donation amounts to 2.4 million bottles each year -- but activists say it isn't enough.
The U.S. government, which developed and patented the use of Truvada for PrEP, got nothing.
Samira Wiley and Alexis Bledel speak with The Advocate about solidarity, sisterhood, and taking on the patriarchy.